Document is current
Any future updates will be listed below
-
Authors
Motoki, Hirohiko
Kuwahara, Koichiro
Uchida, Haruhito A.
Wada, Jun
Kario, Kazuomi
Katsuya, Tomohiro
Shimosawa, Tatsuo
Tsujita, Kenichi
Suzuki, Shoko
Suedomi, Tomohiro
Taguchi, Takashi
- License Information
-
More Information
Article History
Received: 27 May 2025
Revised: 31 July 2025
Accepted: 12 August 2025
First Online: 1 September 2025
Compliance with ethical standards
:
: HM has no conflicts of interest to declare. KKuwahara received research funding from Novo Nordisk Pharma Ltd. and Kowa Co., Ltd.; honoraria from MSD K.K., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AstraZeneca K.K., Astellas Pharma Inc., Novo Nordisk Pharma Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Bayer Yakuhin, Ltd., and Pfizer Japan Inc.; scholarships or donations from Otsuka Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Taisho Pharmaceutical Co., Ltd., and Fukuda Denshi Co., Ltd.; and departmental endowments from Abbott Medical Japan LLC., Medtronic Japan Co., Ltd., Biotronik Japan, Inc., Boston Scientific Japan K.K., Japan Lifeline Co., Ltd., Terumo Corporation, Nipro Corporation, and Cordis Japan G.K. HAU has no conflicts of interest to declare. JW received honoraria for speakers’ bureaus from AstraZeneca K.K., and Daiichi Sankyo Co., Ltd. KKario received support for medical writing, article processing charges, research funding, and advisory fees from Daiichi Sankyo Co., Ltd.; grants from Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., Sumitomo Pharma Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd.; consulting fees from Sanwa Chemical Co., Ltd.; honoraria from Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., and Viatris Pharmaceuticals Japan G.K.; and participated in advisory boards for Novartis Pharma K.K. and Daiichi Sankyo Co., Ltd. TK received honoraria from Daiichi Sankyo Co., Ltd., CureApp, Inc., and Novartis Pharma K.K. TShimosawa had employment/leadership position/advisory roles with Sekisui Medical Co., Ltd., and EPS corporation; and received honoraria from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Ion Retail Co., Ltd., and Ion Happicom Co., Ltd. KT received honoraria from Abbott Medical Japan LLC., Amgen K.K., Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Kowa Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Terumo Corporation; research funding from Mochida Pharmaceutical Co., Ltd., and EA Pharma Co., Ltd.; scholarships or donations from Abbott Medical Japan LLC., ITI Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Boston Scientific Japan K.K.; and departmental endowments from Abbott Japan Co., Ltd., Boston Scientific Japan K.K., Fides-one, Inc., GM Medical Co., Ltd., ITI Co., Ltd., Kaneka Medix Co., Ltd., Nipro Corporation, Terumo Corp., Philips Japan Ltd., Getinge Group Japan K.K., Orbusneich Medical K.K., Abbott Medical Japan LLC., Biotronik Japan, Inc., Fukuda Denshi Co., Ltd., Japan Lifeline Co., Ltd., Medtronic Japan Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd. SS, T Suedomi, and TT are employees of Daiichi Sankyo Co., Ltd.
